MSD and Daiichi Sankyo have announced first subject dosing in the IDeate-Prostate01 Phase III trial of ifinatamab deruxtecan ...

Merck and Daiichi Sankyo have announced that the first patient has been dosed in the IDeate-Prostate01 phase 3 trial ...

Merck just kicked off its Phase 3 IDeate-Prostate01 trial, handing the first dose of ifinatamab deruxtecan to a patient ...

The first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus docetaxel in patients with metastatic ...

The crystal structure of B7-consists of a unique combination of two Ig domains. One is characteristic of an adhesion receptor and the other has only been seen previously in antigen receptors 25.

Currently, the debate is purportedly set to take place on both the H3 Podcast and Piker's Twitch stream on Friday, May 2nd, 2025 at 12:30 PST. On April 23rd, 2025, Ethan Klein said during an episode ...

Three United Nations agencies warned on Thursday of looming famine in an area of South Sudan facing violent conflict. People in 11 of 13 counties in South Sudan’s Upper Nile ...

总体来看，明慧医药正在加速将科研价值转化为商业价值，通过战略BD交易实现研发与资本的良性循环。这一切都得益于公司以差异化研发战略构建的多维创新引擎，从而形成了长短结合的创新产品矩阵。

MacroGenics' recent royalty deal extends cash runway, but liquidity concerns remain, and further asset sales or dilution may ...

The Palestinian Health Ministry says Palestinians desperately trying to access aid in Gaza have come under fire again, killing 36 people and wounding 207. Experts and humanitarian aid workers say ...

映恩生物-B（09606）早盘一度涨超13%，盘中高见243.2港元，创上市新高。截至发稿，股价上涨11.66%，报239.40港元，成交额8327.82万港元。

智通财经获悉，映恩生物-B (09606)早盘涨超13%，盘中高见243.2港元，创上市新高。截至发稿，涨10.82%，报237.6港元，成交额8244.2万港元。